Citius Pharmaceuticals (CTXR) investor relations material

Company overview and business model

• Focuses on developing and commercializing first-in-class critical care biopharmaceutical products addressing unmet medical needs, with an emphasis on reformulations of approved drugs to reduce development risk.

• Pipeline includes Mino-Lok (antibiotic lock solution), Halo-Lido (topical corticosteroid-lidocaine), and NoveCite (stem cell therapy for ARDS); majority-owned subsidiary Citius Oncology markets LYMPHIR for cutaneous T-cell lymphoma.

• Operates through wholly- and majority-owned subsidiaries, with headquarters in Cranford, NJ.

Financial performance and metrics

• Closed a registered direct offering and concurrent private placement in April 2026, raising approximately $4.5 million in net proceeds.

• Received $3.8 million in non-dilutive capital through New Jersey's Net Operating Loss Program in February 2026.

• As of March 31, 2026, had 22,376,427 shares outstanding, with up to 32,884,043 shares to be outstanding after the offering, assuming full warrant exercise.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; may receive up to $4.8 million in gross proceeds if all warrants are exercised for cash.

• Any proceeds from warrant exercises are allocated to working capital, with no specific allocation to projects.